Lidocaine and Epinephrine for Newborns (Neonates, 0 to 28 Days)
No standard dose
No dose is shown for newborns. The labels give no information specific to this age, so the page takes the safer choice.
AAPD, for information only: "Doses of amides should be decreased by 30% in infants younger than 6 months." (AAPD 2023, Table note B)
Lidocaine and Epinephrine for Infants (1 to 12 Months)
No standard dose
No dose is shown for infants. The labels give no information specific to this age, so the page takes the safer choice.
AAPD, for information only: "Doses of amides should be decreased by 30% in infants younger than 6 months." (AAPD 2023, Table note B)
Lidocaine and Epinephrine Dose for Children 1 to 9 Years
Max 4.4 mg/kg lidocaine (AAPD), never over 7 mg/kg
Special situations, children 1 to 9
With kidney disease
No dose change in the labels. Metabolites may build up.
"Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites." (Flavalta 12.3)
With liver disease
Consider a lower dose and closer monitoring in moderate to severe liver disease. The label gives no number.
"...consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment..." (Flavalta 8.6)
On dialysis
Not covered by the labels.
The labels do not mention dialysis.
With heart disease
Give reduced doses. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.
"...should also be given in reduced doses in patients with impaired cardiovascular function (e.g., hypotension, heart block)..." (Flavalta 5.6) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)
Taking interacting medicines
No dose change in the labels. Avoid if possible, otherwise monitor closely. MAO inhibitors, tricyclic antidepressants and nonselective beta blockers can cause severe high blood pressure. Ergot-type oxytocics can cause severe high blood pressure or stroke. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.
"Concurrent use of these agents should generally be avoided." (Flavalta 7.2, 7.4, 7.7) · "Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs" (Flavalta 7.3)
At risk of methemoglobinemia
No dose change in the labels. Monitor closely when other oxidizing drugs are given, including other local anesthetics, nitrates, dapsone and sulfonamides.
"Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics" (Flavalta 7.5)
Sulfite allergy
Contains a sulfite (potassium metabisulfite in Flavalta).
"...such as the sulfites in epinephrine-containing solutions" (Flavalta 17)
Lidocaine and Epinephrine Dose for Children 10 to 16 Years
Max 4.4 mg/kg lidocaine (AAPD), never over 7 mg/kg or 500 mg
Special situations, children 10 to 16
With kidney disease
No dose change in the labels. Metabolites may build up.
"Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites." (Flavalta 12.3)
With liver disease
Consider a lower dose and closer monitoring in moderate to severe liver disease. The label gives no number.
"...consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment..." (Flavalta 8.6)
On dialysis
Not covered by the labels.
The labels do not mention dialysis.
With heart disease
Give reduced doses. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.
"...should also be given in reduced doses in patients with impaired cardiovascular function (e.g., hypotension, heart block)..." (Flavalta 5.6) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)
Taking interacting medicines
No dose change in the labels. Avoid if possible, otherwise monitor closely. MAO inhibitors, tricyclic antidepressants and nonselective beta blockers can cause severe high blood pressure. Ergot-type oxytocics can cause severe high blood pressure or stroke. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.
"Concurrent use of these agents should generally be avoided." (Flavalta 7.2, 7.4, 7.7) · "Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs" (Flavalta 7.3)
At risk of methemoglobinemia
No dose change in the labels. Monitor closely when other oxidizing drugs are given, including other local anesthetics, nitrates, dapsone and sulfonamides.
"Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics" (Flavalta 7.5)
Sulfite allergy
Contains a sulfite (potassium metabisulfite in Flavalta).
"...such as the sulfites in epinephrine-containing solutions" (Flavalta 17)
In pregnancy
No dose change in the labels.
"Available published data and decades of clinical use with lidocaine in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes." (Flavalta 8.1)
While breastfeeding
No dose change in the labels. Lidocaine passes into milk in low amounts and is poorly absorbed by mouth.
"Published data report the presence of lidocaine and its metabolites in human milk in low amounts, along with poor oral bioavailability." (Flavalta 8.2)
Lidocaine and Epinephrine Dose for Adults (17 to 64)
Max 7 mg/kg lidocaine, never over 500 mg, healthy adults
Special situations, adults
With kidney disease
No dose change in the labels. Metabolites may build up.
"Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites." (Flavalta 12.3)
With liver disease
Consider a lower dose and closer monitoring in moderate to severe liver disease. The label gives no number.
"...consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment..." (Flavalta 8.6)
On dialysis
Not covered by the labels.
The labels do not mention dialysis.
With heart disease
Give reduced doses. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.
"...should also be given in reduced doses in patients with impaired cardiovascular function (e.g., hypotension, heart block)..." (Flavalta 5.6) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)
Taking interacting medicines
No dose change in the labels. Avoid if possible, otherwise monitor closely. MAO inhibitors, tricyclic antidepressants and nonselective beta blockers can cause severe high blood pressure. Ergot-type oxytocics can cause severe high blood pressure or stroke. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.
"Concurrent use of these agents should generally be avoided." (Flavalta 7.2, 7.4, 7.7) · "Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs" (Flavalta 7.3)
At risk of methemoglobinemia
No dose change in the labels. Monitor closely when other oxidizing drugs are given, including other local anesthetics, nitrates, dapsone and sulfonamides.
"Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics" (Flavalta 7.5)
Sulfite allergy
Contains a sulfite (potassium metabisulfite in Flavalta).
"...such as the sulfites in epinephrine-containing solutions" (Flavalta 17)
In pregnancy
No dose change in the labels.
"Available published data and decades of clinical use with lidocaine in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes." (Flavalta 8.1)
While breastfeeding
No dose change in the labels. Lidocaine passes into milk in low amounts and is poorly absorbed by mouth.
"Published data report the presence of lidocaine and its metabolites in human milk in low amounts, along with poor oral bioavailability." (Flavalta 8.2)
Lidocaine and Epinephrine Dose for Older Adults (65 and Older)
Max 7 mg/kg lidocaine, never over 500 mg, reduced doses advised
Special situations, older adults
With kidney disease
No dose change in the labels. Metabolites may build up.
"Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites." (Flavalta 12.3)
With liver disease
Consider a lower dose and closer monitoring in moderate to severe liver disease. The label gives no number.
"...consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment..." (Flavalta 8.6)
On dialysis
Not covered by the labels.
The labels do not mention dialysis.
With heart disease
Give reduced doses. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.
"...should also be given in reduced doses in patients with impaired cardiovascular function (e.g., hypotension, heart block)..." (Flavalta 5.6) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)
Taking interacting medicines
No dose change in the labels. Avoid if possible, otherwise monitor closely. MAO inhibitors, tricyclic antidepressants and nonselective beta blockers can cause severe high blood pressure. Ergot-type oxytocics can cause severe high blood pressure or stroke. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.
"Concurrent use of these agents should generally be avoided." (Flavalta 7.2, 7.4, 7.7) · "Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs" (Flavalta 7.3)
At risk of methemoglobinemia
No dose change in the labels. Monitor closely when other oxidizing drugs are given, including other local anesthetics, nitrates, dapsone and sulfonamides.
"Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics" (Flavalta 7.5)
Sulfite allergy
Contains a sulfite (potassium metabisulfite in Flavalta).
"...such as the sulfites in epinephrine-containing solutions" (Flavalta 17)
Sources
18 FDA labels, AAPD 2023, Becker 2006
What each number comes from
- 7 mg/kg and 500 mg
- Every dental label: "kept below 500 mg" and never over "7 mg/kg" of body weight (Flavalta 2.2; same in Xylocaine Dental).
- 4.4 mg/kg, children
- "The table lists the long-established pediatric dental maximum dose of lidocaine as 4.4 mg/kg; however, the MRD is 7 mg/kg." (AAPD 2023, Table note C)
- 20 mg/mL
- Lidocaine HCl 2%, every listing in the FDA NDC Directory.
- 0.01 and 0.02 mg/mL
- Epinephrine 1:100,000 and 1:50,000, FDA NDC Directory.
- 0.04 mg epinephrine
- Conservative limit with significant heart disease, per 30 minutes (Becker and Reed 2006). Not an AHA limit. Its origin is a textbook (Davis 2010, J Can Dent Assoc).
- Two anesthetics
- Maximums add up (Becker and Reed 2006). No guideline body publishes a formula.
- Retrieved
- Nov 15, 2026. All 18 labels active in the FDA NDC Directory.
All 18 dental labels checked
- Xylocaine, Dentsply Pharmaceutical NDC 66312-176, 66312-181, label of 2026-08-13
- Lidocaine, Henry Schein Inc. NDC 0404-6500, label of 2026-04-23
- Lidocaine, Novocol Pharmaceutical of Canada, Inc. NDC 51004-2105, label of 2026-03-26
- Lidocaine, Darby Dental Supply, LLC NDC 66467-9710, label of 2026-07-27
- Flavalta, Septodont, Inc. NDC 0362-1200, label of 2026-03-31
- Lidocaine, The Atlanta Dental Supply Company DBA Advanced Dental Products NDC 71347-210, label of 2026-08-10
- Lidocaine, Patterson Dental NDC 50227-1030, label of 2026-07-28
- Lidocaine, Safco Dental Supply Co NDC 67239-0240, label of 2026-10-08
- Lidocaine, Septodont, Inc. NDC 0362-0898, label of 2026-08-11
- Lidocaine, NDC, Inc. NDC 43128-105, label of 2026-08-06
- Lidocaine, Benco Dental NDC 66975-415, label of 2026-07-28
- Lidocaine, Benco Dental NDC 66975-425, label of 2026-07-30
- Lidocaine, Septodont, Inc. NDC 0362-0262, label of 2026-08-10
- Lidocaine, Darby Dental Supply, LLC NDC 66467-9730, label of 2026-07-27
- Lidocaine, Patterson Dental NDC 50227-1020, label of 2026-07-27
- Lignospan Forte, Septodont, Inc. NDC 0362-1096, label of 2025-03-20
- Lidocaine, Henry Schein Inc. NDC 0404-6512, label of 2026-04-23
- Lignospan Standard, Septodont, Inc. NDC 0362-1095, label of 2025-03-20
Same limits in all of them. Flavalta (Mar 2026) is the newest format and is cited by section number.
Not used here
7 lidocaine and epinephrine vials and ampules for general injection (Hospira and others). Their dosing differs, so they get their own page.